Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Accured Expenses (2020 - 2026)

SAB Biotherapeutics filings provide 7 years of Change in Accured Expenses readings, the most recent being -$1.2 million for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 304.94% to -$1.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$836515.0, a 189.77% decrease, with the full-year FY2025 number at $941524.0, up 176.48% from a year prior.
  • Change in Accured Expenses hit -$1.2 million in Q1 2026 for SAB Biotherapeutics, down from -$394856.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.9 million in Q3 2024 to a low of -$2.0 million in Q2 2022.
  • Median Change in Accured Expenses over the past 5 years was -$394856.0 (2025), compared with a mean of -$337477.3.
  • Biggest five-year swings in Change in Accured Expenses: soared 1661.16% in 2025 and later crashed 304.94% in 2026.
  • SAB Biotherapeutics' Change in Accured Expenses stood at -$320231.0 in 2022, then skyrocketed by 538.06% to $1.4 million in 2023, then crashed by 202.66% to -$1.4 million in 2024, then skyrocketed by 72.58% to -$394856.0 in 2025, then tumbled by 202.63% to -$1.2 million in 2026.
  • The last three reported values for Change in Accured Expenses were -$1.2 million (Q1 2026), -$394856.0 (Q4 2025), and -$287490.0 (Q3 2025) per Business Quant data.